NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 11/17/2025 at 14:30, 4 months 8 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. files Form 10-Q for Q3 2025 with SEC, presents NV-387 as broad-spectrum antiviral drug addressing unmet medical needs. Company strengthens financial position with recent financings

NanoViricides NV-387 Financings Form 10-Q Antiviral Drug
BRIEF

published on 11/14/2025 at 14:35, 4 months 11 days ago

NanoViricides présente le NV-387 au Pharma Partnering Summit 2025

NanoViricides NV-387 Médicaments Antiviraux Grippe H3N2 Sommet Des Partenariats Pharmaceutiques 2025
BRIEF

published on 11/14/2025 at 14:35, 4 months 11 days ago

NanoViricides Highlights NV-387 at Pharma Partnering Summit 2025

NanoViricides NV-387 Antiviral Drugs Influenza H3N2 Pharma Partnering Summit 2025
PRESS RELEASE

published on 11/14/2025 at 14:30, 4 months 11 days ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NanoViricides, Inc. to present NV-387, a revolutionary broad-spectrum antiviral drug, at Pharma Partnering Summit 2025. NV-387 mimics virus features to combat viral infections effectively

NanoViricides NV-387 Antiviral Drug Clinical Stage Pharma Partnering Summit 2025
BRIEF

published on 11/12/2025 at 23:06, 4 months 13 days ago

NanoViricides finalise une levée de fonds de 6 millions de dollars

Placement Privé Mandats Offre Directe Conformité SEC Développement Antiviral
BRIEF

published on 11/12/2025 at 23:06, 4 months 13 days ago

NanoViricides Finalizes $6 Million Funding Round

Private Placement Warrants SEC Compliance Direct Offering Antiviral Development
PRESS RELEASE

published on 11/12/2025 at 23:01, 4 months 13 days ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces closing of $6 million offering with healthcare investor. Proceeds for working capital. AGP/Alliance acted as placement agent

NanoViricides Securities Purchase Agreement Registered Direct Offering Healthcare Investor AGP/Alliance
BRIEF

published on 11/11/2025 at 14:35, 4 months 14 days ago

NanoViricides annonce une levée de fonds de 6 millions de dollars par le biais d'offres directes et de placements privés.

NanoViricides Placement Privé Bons De Souscription D'actions Offre Directe Investisseur Dans Le Secteur De La Santé
BRIEF

published on 11/11/2025 at 14:35, 4 months 14 days ago

NanoViricides Announces $6 Million Fundraising Through Direct Offering and Private Placement

Private Placement NanoViricides Direct Offering Stock Warrants Healthcare Investor
PRESS RELEASE

published on 11/11/2025 at 14:30, 4 months 14 days ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes

NanoViricides Securities Purchase Agreement Registered Direct Offering Warrants Pharmaceutical Candidates

Published on 03/26/2026 at 04:55, 2 hours 36 minutes ago

Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 6 hours 51 minutes ago

Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 7 hours 1 minute ago

Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 12 hours 16 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 18 hours 1 minute ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada

View all ACCESSWIRE

Published on 03/26/2026 at 07:27, 4 minutes ago

Delivery Hero reports adj EBITDA up 30% in 2025, as Quick Commerce and key markets gain momentum
Published on 03/26/2026 at 07:11, 19 minutes ago

Berentzen-Gruppe Aktiengesellschaft publishes its 2025 Annual Report – Berentzen Group achieves significant consolidated profit
Published on 03/26/2026 at 07:07, 23 minutes ago

Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
Published on 03/26/2026 at 07:05, 25 minutes ago

Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children
Published on 03/26/2026 at 07:05, 26 minutes ago

EDAG Group: Market uncertainty and delayed awarding of projects shape FY 2025 – Strategic measures accelerated to restore sustainable growth and competitiveness

View all EQS

Published on 03/25/2026 at 18:53, 12 hours 37 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Published on 03/25/2026 at 18:53, 12 hours 37 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 13 hours ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 18:31, 13 hours ago

Performance soutenue des Investissements et déploiement actif de la stratégie
Published on 03/25/2026 at 18:06, 13 hours 24 minutes ago

LNA SANTE : Résultats Annuels 2025

View all LES ECHOS COMFI WIRE

News